The S2D project, “from splice sequencing to drug”, consists to the exhaustive analysis by RNA sequencing of molecular modifications and especially the alternative splicing induced in human samples by treatment with marketed drugs. The identified molecular events on biomarkers of monogenic diseases will be exploited for the repositioning of the studied drug as potential new therapeutic candidates for rare diseases. The libraries produced from human embryonic stem cells derivatives treated by 50 marketed drugs are currently under analysis.
